(Q38592363)

English

Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.

scientific article published on 25 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

M Cutolo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

E C Keystone

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

W Park

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

J Braun

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

0 references

publication date

25 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Journal of Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

279

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

41-59

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Inequities in access to biologic and synthetic DMARDs across 46 European countries

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Developing oncology biosimilars: an essential approach for the future

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilar insulins: how similar is similar?

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

The challenge of indication extrapolation for infliximab biosimilars

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilars: the science of extrapolation

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Statistical and regulatory considerations in assessments of interchangeability of biological drug products

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Pharmacovigilance of biopharmaceuticals: challenges remain

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilars: pharmacovigilance and risk management

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Physicochemical characterization of Remsima

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biologic therapies in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

The role of biosimilars in the treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilars to treat inflammatory arthritis: the challenge of proving identity

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilars in rheumatology: the wind of change

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Biosimilars in IBD: hope or expectation?

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

The biosimilar road in inflammatory bowel disease: the right way?

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Clinical experience with Zarzio® in Europe: what have we learned?

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Patient Perspectives on Biosimilar Insulin

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Burden of disease in treated rheumatoid arthritis patients: going beyond the joint

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12432

21 January 2018

Identifiers

10.1111/JOIM.12432

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403380%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38592363&oldid=1647953182"